Pim kinase inhibitors and methods of their use

Details for Australian Patent Application No. 2008221263 (hide)

Owner Novartis AG

Inventors Huh, Kay; Garcia, Pablo; Han, Wooseok; Zavorotinskaya, Tatiana; Nishiguchi, Gisele; Antonios-Mccrea Jr., William; Burger, Matthew; Atallah, Gordana; McBride, Christopher; Lindvall, Mika; Bellamacina, Cornelia; Shafer, Cynthia; Lan, Jiong; Walter, Annette

Agent Davies Collison Cave

Pub. Number AU-B-2008221263

PCT Pub. Number WO2008/106692

Priority 61/023,777 25.01.08 US; 60/892,444 01.03.07 US

Filing date 3 March 2008

Wipo publication date 4 September 2008

Acceptance publication date 23 February 2012

International Classifications

C07D 213/78 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/44 (2006.01) - Non-condensed pyridines

A61P 35/00 (2006.01) Antineoplastic agents

C07D 239/28 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

1 October 2009 PCT application entered the National Phase

  PCT publication WO2008/106692 Priority application(s): WO2008/106692

23 February 2012 Application Accepted

  Published as AU-B-2008221263

21 June 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008221264-Enhanced aerial delivery system

2008221260-Breakthrough pain management